Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals, Inc. is a U.S.-based clinical-stage biopharmaceutical company developing small-molecule drug candidates for cancer and other therapeutic areas. Its pipeline includes next-generation oncology programs such as NGC-Cap, NGC-Gem, and NGC-Iri, along with two non-oncology candidates that may be pursued through partnering or licensing.

2.54

2.54

— Processa Pharmaceuticals, Inc.
%
Oncology pipeline0% Small-molecule cancer therapy candidates designed to improve efficacy and reduce toxicity.
Non-oncology pipeline0% Additional drug candidates outside oncology that may be advanced or partnered.
Drug development services100% Internal research, preclinical work, and clinical trial execution for company-owned assets.

Processa does not currently sell approved products; its economic counterparties are primarily clinical research...

  • Clinical research organizations and trial sitesprimary

    They perform and manage preclinical studies and clinical trials for Processa's drug candidates.

  • Research institutionsprimary

    They provide scientific services, testing, and study execution support for development programs.

  • Potential licensing and collaboration partnerssecondary

    They may acquire rights to non-oncology assets or co-develop programs to share risk and funding.

  • Future oncology prescribers and patientsemerging

    They would use approved therapies if the company's oncology candidates reach commercialization.

Processa is headquartered in the United States and its development, financing, and regulatory activities are centered...

  • •United States is the core operating and financing base
  • •FDA oversight is central to development and approval risk
  • •Clinical trial activity may involve U.S. and foreign sites
  • •Future commercialization would depend on approved market geographies
  • •No country-level revenue is disclosed because no products are approved

The company is focused on advancing a small pipeline of next-generation cancer therapies using a regulatory science...

01
Advance NGC-Cap and other oncology candidates through clinical developmentshort-term

Clinical data is the main value driver for a biopharma pipeline and determines future partnering or approval potential.

02
Use regulatory science to improve approval probabilitymedium-term

A clearer regulatory path can reduce development risk and improve the attractiveness of the assets to partners.

03
Monetize non-oncology assets through partneringmedium-term

Out-licensing can create non-dilutive funding and reduce the need to carry every program internally.

The company faces the core risks of clinical-stage drug development: trial failure, safety issues, regulatory delays,...

critical

Clinical development failure

Drug candidates can be halted if scientific progress is insufficient or results are not commercially viable.

Scope
All pipeline programs
Materiality
high
high

Regulatory delay or non-approval

FDA and other agencies can delay, request more data, or reject applications, extending timelines and costs.

Scope
Oncology pipeline
Materiality
high
high

Financing and dilution risk

The company depends on equity, debt, or partnering to fund operations until commercialization.

Scope
Corporate-wide
Materiality
high
medium

Clinical trial execution and accrual estimation risk

Trial costs depend on enrollment, site activity, and third-party performance, which can differ from estimates.

Scope
R&D expense recognition
Materiality
medium
medium

Nasdaq listing compliance risk

Failure to meet exchange requirements could reduce liquidity and access to capital.

Scope
Public equity market access
Materiality
medium
Clinical trial accrual estimates
Quarterly R&D comparability
Preclinical and clinical prepaid expenses
Balance sheet and period expense timing
Going-concern and financing dependence
Liquidity presentation and investor assessment

Erasca, Inc.

ERAS · Pharmaceutical Preparations

Oric Pharmaceuticals, Inc.

ORIC · Pharmaceutical Preparations

Propanc Biopharma, Inc.

PPCB · Pharmaceutical Preparations

Vincerx Pharma, Inc.

Pharmaceutical Preparations

Olema Pharmaceuticals, Inc.

OLMA · Pharmaceutical Preparations

Pyxis Oncology, Inc.

PYXS · Pharmaceutical Preparations

: 29/04/2026